中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

30 records (took 0.047 seconds)

    Imidazo[4,5-d]pyrimidines, their uses and methods of preparation
    2.
    发明申请
    Imidazo[4,5-d]pyrimidines, their uses and methods of preparation 有权
    咪唑并[4,5-d]嘧啶，其用途和制备方法

    公开(公告)号：US20060052602A1

    公开(公告)日：2006-03-09

    申请号：US11190751

    申请日：2005-07-26

    Applicant: Choung Kim ,  Johan Neyts ,  David Oare ,  Gerhard Puerstinger

    Inventor： Choung Kim ,  Johan Neyts ,  David Oare ,  Gerhard Puerstinger

    IPC: C07D473/02

    CPC classification number: C07D471/04 ,  C07D473/00 ,  C07D473/30

    Abstract: The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyrimidine having the general formula (A): wherein the substituents are described in the specification. The invention also relates to processes for the preparation of compounds according to the invention having above mentioned general formula, their pharmaceutically acceptable formulations and their use as a medicine or to treat or prevent viral infections.

    Abstract translation: 本发明涉及用于治疗或预防病毒感染的药物组合物，其包含作为活性成分的至少一种具有通式（A）的咪唑并[4,5-c]嘧啶：

    Receptor specific atrial natriuretic peptides
    9.
    发明授权
    Receptor specific atrial natriuretic peptides 有权
    受体特异性心房利钠肽

    公开(公告)号：US06525022B1

    公开(公告)日：2003-02-25

    申请号：US09154390

    申请日：1998-09-16

    Applicant: David G. Lowe ,  Brian C. Cunningham ,  David Oare ,  Robert S. McDowell ,  John P. Burnier

    Inventor： David G. Lowe ,  Brian C. Cunningham ,  David Oare ,  Robert S. McDowell ,  John P. Burnier

    IPC: A61K3812

    CPC classification number: C07K14/58 ,  A61K38/00

    Abstract: Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.

    Abstract translation: 含有各种取代，特别是G16R的人受体选择性心房利钠因子变体对人A受体显示相同的效力和结合亲和力，但对人清除或C-受体的亲和力降低。 这些ANF变体具有利钠，利尿和血管舒张活性，但具有增加的代谢稳定性，使其适合于治疗充血性心力衰竭，急性肾衰竭和肾性高血压。

    Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds
    10.
    发明授权
    Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds 有权
    取代的4-氨基-1-（吡啶基甲基）哌啶及相关化合物

    公开(公告)号：US08030502B2

    公开(公告)日：2011-10-04

    申请号：US11974982

    申请日：2007-10-17

    Applicant: Mathai Mammen ,  David Oare ,  Junning Lee ,  Weijiang Zhang

    Inventor： Mathai Mammen ,  David Oare ,  Junning Lee ,  Weijiang Zhang

    IPC: C07D207/08

    CPC classification number: C07D401/14

    Abstract: This invention provides 4-amino-1-(pyridylmethyl)piperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome and chronic obstructive pulmonary disease, using such compounds.

    Abstract translation: 本发明提供了可用作毒蕈碱受体拮抗剂的4-氨基-1-（吡啶基甲基）哌啶及其相关化合物及其药学上可接受的盐。 本发明还提供含有这些化合物的药物组合物; 用于制备这些化合物的方法和中间体; 以及使用这些化合物治疗由毒蕈碱受体介导的疾病状况的方法，例如膀胱过度活动，肠易激综合征和慢性阻塞性肺疾病。

Patent Agency Ranking